Gilead Sciences Inc (GILD)

Apr 18, 2025

What Analyst Projections for Key Metrics Reveal About Gilead (GILD) Q1 Earnings - MSN

Apr 18, 2025

Apr 18, 2025

Here's Why Gilead Sciences (GILD) is a Strong Value Stock - Yahoo Finance

Apr 18, 2025

Apr 17, 2025

BMO Capital Adjusts Gilead Sciences Price Target to $120 From $115 - MarketScreener

Apr 17, 2025

Apr 17, 2025

Leerink Partners Adjusts Price Target on Gilead Sciences to $105 From $104, Keeps Outperform Rating - MarketScreener

Apr 17, 2025

Apr 17, 2025

Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance

Apr 17, 2025

Apr 17, 2025

News - Department of Health Abu Dhabi

Apr 17, 2025

Apr 17, 2025

DoH Partners with Gilead Sciences to propel healthcare innovation and cell therapy advancement - ZAWYA

Apr 17, 2025

Apr 17, 2025

Nurix Says FDA Clears Oral IRAK4 Degrader Application for Inflammatory Diseases; Shares Up Pre-Bell - marketscreener.com

Apr 17, 2025

Apr 17, 2025

2 High-Yielding ETFs Retirees Can Safely Build Their Portfolios Around - The Motley Fool

Apr 17, 2025

Apr 16, 2025

Gilead Sciences (GILD) Stock Moves -0.74%: What You Should Know - MSN

Apr 16, 2025

Apr 16, 2025

Gilead Sciences CFO sells $266,000 in stock - Investing.com

Apr 16, 2025

Apr 16, 2025

Gilead Sciences CFO sells $266,000 in stock By Investing.com - Investing.com India

Apr 16, 2025

Apr 16, 2025

Gilead Sciences: Advancing Oncology Care Through Gilead's Research Scholars Program - CSRwire

Apr 16, 2025

Apr 16, 2025

Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now? - Yahoo Finance

Apr 16, 2025

Apr 16, 2025

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - MSN

Apr 16, 2025

Apr 16, 2025

Is Gilead Sciences Inc. (NASDAQ:GILD) the Most Undervalued Quality Stock to Buy Now? - Insider Monkey

Apr 16, 2025

Apr 16, 2025

Bridgewater Associates LP Boosts Stake in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

Apr 16, 2025

Apr 15, 2025

11 Most Undervalued Quality Stocks to Buy Now - Insider Monkey

Apr 15, 2025

Apr 15, 2025

Lobbying Update: $75,000 of GILEAD SCIENCES INC. lobbying was just disclosed - Nasdaq

Apr 15, 2025

Apr 15, 2025

Goldman Sachs Adjusts Price Target on Gilead Sciences to $97 From $96, Maintains Neutral Rating - MarketScreener

Apr 15, 2025

Apr 15, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 15, 2025

Apr 15, 2025

Revenues Working Against Gilead Sciences, Inc.'s (NASDAQ:GILD) Share Price - simplywall.st

Apr 15, 2025

Apr 14, 2025

GILD Stock Price and Chart — NASDAQ:GILD - TradingView

Apr 14, 2025

Apr 14, 2025

EPO board revives Gilead patent, sends case back for review - MLex

Apr 14, 2025

Apr 14, 2025

Gilead patent partially upheld by EPO, Teva and STADA's challenge continues - MLex

Apr 14, 2025

Apr 14, 2025

Here's What to Expect From Gilead Sciences’ Next Earnings Report - Nasdaq

Apr 14, 2025

Apr 14, 2025

Gilead reprimanded after PMCPA finds conference Wi-Fi sponsorship broke advertising rules - Fierce Pharma

Apr 14, 2025

Apr 14, 2025

Here's What To Expect From Gilead Sciences’ Next Earnings Report - Barchart.com

Apr 14, 2025

Apr 11, 2025

Gilead Sciences, Trusaic Data Breach Lawsuit Investigation - ClassAction.org

Apr 11, 2025

Apr 11, 2025

PatientView Ranks Gilead “Best” at ESG - CSRwire

Apr 11, 2025

Apr 11, 2025

Gilead Sciences Inc (GILD) Shares Gap Down to $100.87 on Apr 10 - GuruFocus

Apr 11, 2025

Apr 10, 2025

Gilead Sciences To Release First Quarter 2025 Financial Results On Thursday, April 24, 2025 - MarketScreener

Apr 10, 2025

Apr 10, 2025

Gilead Sciences Announces Q1 Estimated Acquired IPR&D - MarketScreener

Apr 10, 2025

Apr 10, 2025

Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025 | GILD Stock News - GuruFocus

Apr 10, 2025

Apr 10, 2025

Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025 - Business Wire

Apr 10, 2025

Apr 10, 2025

AI-startup Prezent names Gilead Sciences’ exec to Board - StartUp Beat

Apr 10, 2025

Apr 10, 2025

PatientView Ranks Gilead "Best" at ESG - MarketScreener

Apr 10, 2025

Apr 10, 2025

Gilead is urged to rework licensing deals for groundbreaking HIV prevention drug - statnews.com

Apr 10, 2025

Apr 10, 2025

Ideaya Biosciences Begins Phase 1/2 Expansion in Urothelial Cancer Treatment Trial in Combination With Gilead's Trodelvy - MarketScreener

Apr 10, 2025

Apr 10, 2025

Manufacturer’s plans for equitable access to twice-yearly PrEP under fire - Aidsmap

Apr 10, 2025

Apr 09, 2025

Mich. Panel: Gilead Immune From Recalled COVID Drug Suit - Law360

Apr 09, 2025

Apr 09, 2025

Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know - Yahoo Finance

Apr 09, 2025

Apr 09, 2025

Gilead, Michigan Hospital Win Appeal Over Tainted Covid-19 Drug - Bloomberg Law News

Apr 09, 2025

Apr 09, 2025

Gilead Sciences (GILD) Anticipates Earnings Surprise - GuruFocus

Apr 09, 2025

Apr 09, 2025

Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance

Apr 09, 2025

Apr 09, 2025

AIDSVu Online Mapping Tool Helps Visualize HIV’s Impact in the United States - Gilead Sciences

Apr 09, 2025

Apr 09, 2025

Gilead Sciences: The Global Health Challenge of HIV and Hepatitis B Coinfections - CSRwire

Apr 09, 2025

Apr 09, 2025

Multiple Tailwinds Lifted Gilead Sciences (GILD) in Q1 - Insider Monkey

Apr 09, 2025

Apr 09, 2025

Weekly CFO Sells Highlight: Adobe Systems, Gilead Sciences and A - GuruFocus

Apr 09, 2025

Apr 08, 2025

July 18th Options Now Available For Gilead Sciences (GILD) - Nasdaq

Apr 08, 2025

Apr 08, 2025

Gilead Sciences describes new nucleoside prodrugs for viral infections - BioWorld MedTech

Apr 08, 2025